Highbridge Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Highbridge Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-15,000	Closed	-$420K	–	1231
2017 Q1	$420K	Sell	15,000 -5,000	-25%	-$126K	0.01%	981
2016 Q4	$405K	Buy	+20,000	New	+$399K	0.01%	853

Other funds holding ASND

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Highbridge Capital Management's ASND Position: Q2 2017 in Review

Highbridge Capital Management sold out of Ascendis Pharma A/S (ASND) in Q2 2017, closing a stake of 15,000 shares — an estimated $420K sold.

Highbridge Capital Management first reported a position in ASND in Q4 2016 and held it in 2 quarters. The position peaked at $420K in Q1 2017. 34 funds tracked by Wall St. Rank hold ASND as of Q2 2017.

Highbridge Capital Management reported no remaining Ascendis Pharma A/S position as of Q2 2017 after selling out during the quarter.
Highbridge Capital Management sold 15,000 Ascendis Pharma A/S shares in Q2 2017, an estimated $420K.
Highbridge Capital Management first reported a position in Ascendis Pharma A/S in Q4 2016 and held it in 2 quarters.
Highbridge Capital Management's Ascendis Pharma A/S position peaked at $420K in Q1 2017.
34 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.